These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 17869296

  • 1. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study.
    Gacci M, Del Popolo G, Macchiarella A, Celso M, Vittori G, Lapini A, Serni S, Sandner P, Maggi M, Carini M.
    J Urol; 2007 Nov; 178(5):2040-3; discussion 2044. PubMed ID: 17869296
    [Abstract] [Full Text] [Related]

  • 2. Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury.
    Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE, Pommerville PJ, Colopy MW, Wachs BH, Vardenafil Study Group.
    Spine (Phila Pa 1976); 2008 Apr 01; 33(7):709-15. PubMed ID: 18379396
    [Abstract] [Full Text] [Related]

  • 3. Up-titration of vardena fi l dose from 10 mg to 20 mg improved erectile function in men with spinal cord injury.
    Kimoto Y, Sakamoto S, Fujikawa K, Tachibana T, Yamamoto N, Otani T.
    Int J Urol; 2006 Nov 01; 13(11):1428-33. PubMed ID: 17083398
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury.
    Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE, Pommerville PJ, Colopy MW, Wilkins HJ, Wachs BH, Vardenafil Study Group.
    Neurology; 2006 Jan 24; 66(2):210-6. PubMed ID: 16434656
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions.
    Kuo HC.
    J Urol; 2003 Sep 24; 170(3):835-9. PubMed ID: 12913711
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ, Lemack GE, Foote JE, Trop CS.
    Urology; 2009 Oct 24; 74(4):741-5. PubMed ID: 19628264
    [Abstract] [Full Text] [Related]

  • 7. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial.
    Silva C, Silva J, Ribeiro MJ, Avelino A, Cruz F.
    Eur Urol; 2005 Oct 24; 48(4):650-5. PubMed ID: 15961217
    [Abstract] [Full Text] [Related]

  • 8. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.
    Zumbé J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E.
    Eur Urol; 2008 Jul 24; 54(1):204-10. PubMed ID: 18395326
    [Abstract] [Full Text] [Related]

  • 9. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study.
    Porst H, Sharlip ID, Hatzichristou D, Rubio-Aurioles E, Gittelman M, Stancil BN, Smith PM, Wilkins HJ, Pommerville P, Vardenafil Study Group.
    Eur Urol; 2006 Nov 24; 50(5):1086-94; discussion 1094-5. PubMed ID: 16820261
    [Abstract] [Full Text] [Related]

  • 10. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E.
    Eur Urol; 2008 Jun 24; 53(6):1236-44. PubMed ID: 18281145
    [Abstract] [Full Text] [Related]

  • 11. Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction.
    Ishii N, Nagao K, Fujikawa K, Tachibana T, Iwamoto Y, Kamidono S.
    Int J Urol; 2006 Aug 24; 13(8):1066-72. PubMed ID: 16903931
    [Abstract] [Full Text] [Related]

  • 12. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction.
    Gittelman M, McMahon CG, Rodríguez-Rivera JA, Beneke M, Ulbrich E, Ewald S.
    Int J Clin Pract; 2010 Apr 24; 64(5):594-603. PubMed ID: 20456213
    [Abstract] [Full Text] [Related]

  • 13. Variability of detrusor overactivity on repeated filling cystometry in men with urge symptoms: comparison with spinal cord injury patients.
    Ockrim J, Laniado ME, Khoubehi B, Renzetti R, Finazzi Agrò E, Carter SS, Tubaro A.
    BJU Int; 2005 Mar 24; 95(4):587-90. PubMed ID: 15705085
    [Abstract] [Full Text] [Related]

  • 14. Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence.
    Mathers MJ, Klotz T, Brandt AS, Roth S, Sommer F.
    BJU Int; 2008 May 24; 101(9):1129-34. PubMed ID: 18190629
    [Abstract] [Full Text] [Related]

  • 15. The efficacy and safety of flexible-dose vardenafil (levitra) in a broad population of European men.
    Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel TJ, Porst H, European Vardenafil Study Group.
    Eur Urol; 2004 May 24; 45(5):634-41; discussion 641. PubMed ID: 15082207
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction].
    Aliaev IuG, Vinarov AZ, Akhvlediani ND.
    Urologiia; 2007 May 24; (1):45-6, 49. PubMed ID: 17471999
    [Abstract] [Full Text] [Related]

  • 18. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels.
    Jarvi K, Dula E, Drehobl M, Pryor J, Shapiro J, Seger M.
    J Urol; 2008 Mar 24; 179(3):1060-5. PubMed ID: 18206950
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.